免疫检查点抑制剂治疗患者免疫相关不良事件的管理:ASCO指南更新
ASCO召集多学科专家组更新免疫检查点抑制剂(ICPi)相关免疫相关不良事件(irAEs)管理指南,系统综述聚焦2017至2021年证据,共175项研究符合纳入标准;因高质量证据匮乏,推荐基于专家共识,按器官系统给出诊断与管理建议。
要点
- 1级毒性一般继续ICPi并密切监测,但部分神经、血液和心脏毒性除外。
- 2级毒性多可暂停ICPi,症状恢复至≤1级时可考虑恢复,可给予皮质类固醇。
- 3级毒性一般需暂停ICPi并开始高剂量皮质类固醇,至少4-6周内逐渐减量。
核心结论
- 因高质量证据匮乏,irAEs管理推荐基于专家共识,按受累器官系统给出诊断与管理建议。
研究设计与样本
- 多学科专家组(涵盖肿瘤内科、皮肤科、消化科、风湿科、肺科、内分泌科、神经科、血液科、急诊医学、护理、试验专家和倡导专家)更新指南。
- 指南制定包括系统文献综述和非正式共识过程,系统综述聚焦2017年至2021年发表的证据。
- 共175项研究符合系统综述纳入标准并与推荐制定相关。
主要发现
- 1级毒性一般继续ICPi并密切监测,但部分神经、血液和心脏毒性除外。
- 2级毒性多可暂停ICPi,症状恢复至≤1级时可考虑恢复,可给予皮质类固醇。
- 3级毒性一般需暂停ICPi并开始高剂量皮质类固醇,皮质类固醇应在至少4-6周内逐渐减量。
- 部分难治性病例可能需要其他免疫抑制治疗。
- 4级毒性一般推荐永久停用ICPi,但经激素替代控制的內分泌病除外。
关键数值与推荐
- 1级毒性:一般继续ICPi并密切监测,但部分神经、血液和心脏毒性除外。
- 2级毒性:多可暂停ICPi,症状恢复至≤1级时可考虑恢复,可给予皮质类固醇。
- 3级毒性:一般需暂停ICPi并开始高剂量皮质类固醇,至少4-6周内逐渐减量。
- 4级毒性:一般推荐永久停用ICPi,但经激素替代控制的內分泌病除外。
- 难治性病例:可能需要其他免疫抑制治疗。
临床怎么用
- 按器官系统特异性毒性进行诊断和管理。
- 1级毒性一般继续ICPi并密切监测,但部分神经、血液和心脏毒性除外。
- 2级毒性多可暂停ICPi,症状恢复至≤1级时可考虑恢复,可给予皮质类固醇。
- 3级毒性一般需暂停ICPi并开始高剂量皮质类固醇,至少4-6周内逐渐减量。
- 4级毒性一般推荐永久停用ICPi,但经激素替代控制的內分泌病除外。
局限性
- 因高质量证据匮乏,推荐基于专家共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy. METHODS: A multidisciplinary panel of medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, neurology, hematology, emergency medicine, nursing, trialists, and advocacy experts was convened to update the guideline. Guideline development involved a systematic literature review and an informal consensus process. The systematic review focused on evidence published from 2017 through 2021. RESULTS: A total of 175 studies met the eligibility criteria of the systematic review and were pertinent to the development of the recommendations. Because of the paucity of high-quality evidence, recommendations are based on expert consensus. RECOMMENDATIONS: Recommendations for specific organ system-based toxicity diagnosis and management are presented. While management varies according to the organ system affected, in general, ICPi therapy should be continued with close monitoring for grade 1 toxicities, except for some neurologic, hematologic, and cardiac toxicities. ICPi therapy may be suspended for most grade 2 toxicities, with consideration of resuming when symptoms revert ≤ grade 1. Corticosteroids may be administered. Grade 3 toxicities generally warrant suspension of ICPis and the initiation of high-dose corticosteroids. Corticosteroids should be tapered over the course of at least 4-6 weeks. Some refractory cases may require other immunosuppressive therapy. In general, permanent discontinuation of ICPis is recommended with grade 4 toxicities, except for endocrinopathies that have been controlled by hormone replacement. Additional information is available at www.asco.org/supportive-care-guidelines.
引用
- Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021. PMID: 34724392. doi:10.1200/JCO.21.01440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。